Does the media prefer OBIO or HYPR?

In the previous week, Hyperfine had 1 more articles in the media than Orchestra BioMed. MarketBeat recorded 7 mentions for Hyperfine and 6 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 0.35 beat Hyperfine's score of 0.28 indicating that Orchestra BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hyperfine 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is HYPR or RCEL more profitable?

Avita Medical has a net margin of -56.96% compared to Hyperfine's net margin of -210.75%. Avita Medical's return on equity of 0.00% beat Hyperfine's return on equity. Company Net Margins Return on Equity Return on Assets Hyperfine -210.75% -97.88% -61.81% Avita Medical -56.96% N/A -78.53%

Does the media favor HYPR or RCEL?

In the previous week, Hyperfine had 5 more articles in the media than Avita Medical. MarketBeat recorded 7 mentions for Hyperfine and 2 mentions for Avita Medical. Avita Medical's average media sentiment score of 0.39 beat Hyperfine's score of 0.28 indicating that Avita Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperfine 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Avita Medical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, CV or HYPR?

CapsoVision has higher revenue and earnings than Hyperfine. CapsoVision is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CapsoVision $13.55M 24.75 -$25.32M -$0.47 N/A Hyperfine $11.40M 7.30 -$35.57M -$0.38 N/A

Is CV or HYPR more profitable?

Hyperfine has a net margin of -210.75% compared to CapsoVision's net margin of -214.74%. Hyperfine's return on equity of -97.88% beat CapsoVision's return on equity. Company Net Margins Return on Equity Return on Assets CapsoVision -214.74% -177.85% -135.07% Hyperfine -210.75% -97.88% -61.81%

Does the media refer more to CV or HYPR?

In the previous week, Hyperfine had 2 more articles in the media than CapsoVision. MarketBeat recorded 7 mentions for Hyperfine and 5 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.70 beat Hyperfine's score of 0.28 indicating that CapsoVision is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CapsoVision 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Hyperfine 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer HYPR or TMCI?

In the previous week, Hyperfine and Hyperfine both had 7 articles in the media. Treace Medical Concepts' average media sentiment score of 0.78 beat Hyperfine's score of 0.28 indicating that Treace Medical Concepts is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperfine 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Treace Medical Concepts 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TLSI or HYPR?

In the previous week, Hyperfine had 6 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 7 mentions for Hyperfine and 1 mentions for TriSalus Life Sciences. TriSalus Life Sciences' average media sentiment score of 0.52 beat Hyperfine's score of 0.28 indicating that TriSalus Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hyperfine 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Hyperfine (HYPR) Competitors

$0.78 +0.01 (+1.54%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.79 +0.00 (+0.29%)

As of 09/18/2026 07:30 PM Eastern

Compare

HYPR vs. OBIO, RCEL, CV, TMCI, and TLSI

Should you buy Hyperfine stock or one of its competitors? Hyperfine's main competitors and comparable companies include Orchestra BioMed (OBIO), Avita Medical (RCEL), CapsoVision (CV), Treace Medical Concepts (TMCI), and TriSalus Life Sciences (TLSI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Hyperfine compare to Orchestra BioMed?

Orchestra BioMed (NASDAQ:OBIO) and Hyperfine (NASDAQ:HYPR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

In the previous week, Hyperfine had 1 more articles in the media than Orchestra BioMed. MarketBeat recorded 7 mentions for Hyperfine and 6 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 0.35 beat Hyperfine's score of 0.28 indicating that Orchestra BioMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hyperfine	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hyperfine has lower revenue, but higher earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48M	10.91	-$52.70M	-$0.85	N/A
Hyperfine	$11.40M	7.30	-$35.57M	-$0.38	N/A

Orchestra BioMed currently has a consensus price target of $13.17, indicating a potential upside of 116.56%. Hyperfine has a consensus price target of $2.03, indicating a potential upside of 159.12%. Given Hyperfine's higher possible upside, analysts plainly believe Hyperfine is more favorable than Orchestra BioMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Hyperfine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

53.2% of Orchestra BioMed shares are held by institutional investors. Comparatively, 15.0% of Hyperfine shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by company insiders. Comparatively, 26.3% of Hyperfine shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Orchestra BioMed has a net margin of -184.60% compared to Hyperfine's net margin of -210.75%. Hyperfine's return on equity of -97.88% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-184.60%	-149.61%	-54.15%
Hyperfine	-210.75%	-97.88%	-61.81%

Orchestra BioMed has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Hyperfine has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

Summary

Orchestra BioMed and Hyperfine tied by winning 8 of the 16 factors compared between the two stocks.

How does Hyperfine compare to Avita Medical?

Hyperfine (NASDAQ:HYPR) and Avita Medical (NASDAQ:RCEL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

Hyperfine has higher earnings, but lower revenue than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	7.30	-$35.57M	-$0.38	N/A
Avita Medical	$71.61M	4.74	-$48.59M	-$1.44	N/A

Avita Medical has a net margin of -56.96% compared to Hyperfine's net margin of -210.75%. Avita Medical's return on equity of 0.00% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-210.75%	-97.88%	-61.81%
Avita Medical	-56.96%	N/A	-78.53%

In the previous week, Hyperfine had 5 more articles in the media than Avita Medical. MarketBeat recorded 7 mentions for Hyperfine and 2 mentions for Avita Medical. Avita Medical's average media sentiment score of 0.39 beat Hyperfine's score of 0.28 indicating that Avita Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avita Medical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hyperfine has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Avita Medical has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market.

Hyperfine presently has a consensus price target of $2.03, indicating a potential upside of 159.12%. Avita Medical has a consensus price target of $11.40, indicating a potential upside of 3.45%. Given Hyperfine's higher possible upside, analysts clearly believe Hyperfine is more favorable than Avita Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Avita Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

15.0% of Hyperfine shares are held by institutional investors. Comparatively, 27.7% of Avita Medical shares are held by institutional investors. 26.3% of Hyperfine shares are held by company insiders. Comparatively, 2.2% of Avita Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Hyperfine and Avita Medical tied by winning 8 of the 16 factors compared between the two stocks.

How does Hyperfine compare to CapsoVision?

CapsoVision (NASDAQ:CV) and Hyperfine (NASDAQ:HYPR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

CapsoVision has higher revenue and earnings than Hyperfine. CapsoVision is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.55M	24.75	-$25.32M	-$0.47	N/A
Hyperfine	$11.40M	7.30	-$35.57M	-$0.38	N/A

CapsoVision currently has a consensus price target of $9.50, indicating a potential upside of 41.79%. Hyperfine has a consensus price target of $2.03, indicating a potential upside of 159.12%. Given Hyperfine's stronger consensus rating and higher probable upside, analysts clearly believe Hyperfine is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Hyperfine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Hyperfine had 2 more articles in the media than CapsoVision. MarketBeat recorded 7 mentions for Hyperfine and 5 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.70 beat Hyperfine's score of 0.28 indicating that CapsoVision is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CapsoVision	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Hyperfine	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

CapsoVision has a beta of -2.47, suggesting that its stock price is 347% less volatile than the broader market. Comparatively, Hyperfine has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

15.0% of Hyperfine shares are owned by institutional investors. 2.3% of CapsoVision shares are owned by insiders. Comparatively, 26.3% of Hyperfine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Hyperfine has a net margin of -210.75% compared to CapsoVision's net margin of -214.74%. Hyperfine's return on equity of -97.88% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-214.74%	-177.85%	-135.07%
Hyperfine	-210.75%	-97.88%	-61.81%

Summary

Hyperfine beats CapsoVision on 12 of the 16 factors compared between the two stocks.

How does Hyperfine compare to Treace Medical Concepts?

Hyperfine (NASDAQ:HYPR) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Hyperfine has higher earnings, but lower revenue than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	7.30	-$35.57M	-$0.38	N/A
Treace Medical Concepts	$212.69M	1.37	-$59M	-$0.93	N/A

Treace Medical Concepts has a net margin of -28.99% compared to Hyperfine's net margin of -210.75%. Treace Medical Concepts' return on equity of -71.37% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-210.75%	-97.88%	-61.81%
Treace Medical Concepts	-28.99%	-71.37%	-30.49%

15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are owned by institutional investors. 26.3% of Hyperfine shares are owned by insiders. Comparatively, 23.4% of Treace Medical Concepts shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Hyperfine currently has a consensus target price of $2.03, indicating a potential upside of 159.12%. Treace Medical Concepts has a consensus target price of $5.17, indicating a potential upside of 15.14%. Given Hyperfine's stronger consensus rating and higher possible upside, analysts clearly believe Hyperfine is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

In the previous week, Hyperfine and Hyperfine both had 7 articles in the media. Treace Medical Concepts' average media sentiment score of 0.78 beat Hyperfine's score of 0.28 indicating that Treace Medical Concepts is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Treace Medical Concepts	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hyperfine has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, Treace Medical Concepts has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

Summary

Hyperfine beats Treace Medical Concepts on 9 of the 15 factors compared between the two stocks.

How does Hyperfine compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and Hyperfine (NASDAQ:HYPR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

TriSalus Life Sciences has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market. Comparatively, Hyperfine has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

TriSalus Life Sciences has a net margin of -62.59% compared to Hyperfine's net margin of -210.75%. TriSalus Life Sciences' return on equity of 0.00% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-62.59%	N/A	-64.47%
Hyperfine	-210.75%	-97.88%	-61.81%

Hyperfine has lower revenue, but higher earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.15M	6.96	-$39.23M	-$1.30	N/A
Hyperfine	$11.40M	7.30	-$35.57M	-$0.38	N/A

In the previous week, Hyperfine had 6 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 7 mentions for Hyperfine and 1 mentions for TriSalus Life Sciences. TriSalus Life Sciences' average media sentiment score of 0.52 beat Hyperfine's score of 0.28 indicating that TriSalus Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperfine	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

TriSalus Life Sciences currently has a consensus price target of $8.67, indicating a potential upside of 69.93%. Hyperfine has a consensus price target of $2.03, indicating a potential upside of 159.12%. Given Hyperfine's higher possible upside, analysts plainly believe Hyperfine is more favorable than TriSalus Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Hyperfine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 15.0% of Hyperfine shares are owned by institutional investors. 16.3% of TriSalus Life Sciences shares are owned by insiders. Comparatively, 26.3% of Hyperfine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Hyperfine beats TriSalus Life Sciences on 10 of the 14 factors compared between the two stocks.

Get Hyperfine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HYPR vs. The Competition

Export

Metric	Hyperfine	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$83.22M	$5.57B	$7.24B	$12.95B
Dividend Yield	N/A	1.80%	2.57%	12.80%
P/E Ratio	-2.07	25.34	275.49	25.40
Price / Sales	7.30	43.84	642.70	86.83
Price / Cash	N/A	32.64	76.25	51.42
Price / Book	1.87	5.69	10.46	6.33
Net Income	-$35.57M	$151.55M	$3.49B	$358.33M
7 Day Performance	-0.68%	0.66%	0.59%	1.12%
1 Month Performance	-13.21%	-3.33%	-1.74%	-2.39%
1 Year Performance	-45.88%	6.79%	18.13%	5.35%

Hyperfine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HYPR Hyperfine	2.3129 of 5 stars	$0.78 +1.5%	$2.03 +159.1%	-45.9%	$83.22M	$11.40M	N/A	102	News Coverage
OBIO Orchestra BioMed	3.604 of 5 stars	$5.43 +6.9%	$13.00 +139.4%	+149.2%	$326.34M	$33.48M	N/A	4	Analyst Forecast
RCEL Avita Medical	1.1363 of 5 stars	$10.41 -7.1%	$11.40 +9.5%	+101.5%	$320.39M	$75.63M	N/A	130
CV CapsoVision	3.5153 of 5 stars	$6.36 +6.2%	$9.50 +49.4%	+41.4%	$318.30M	$13.89M	N/A	90	News Coverage Positive News Insider Trade
TMCI Treace Medical Concepts	2.9114 of 5 stars	$4.63 -3.7%	$5.17 +11.7%	-34.8%	$301.14M	$212.69M	N/A	250	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HYPR) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hyperfine (HYPR) Competitors

HYPR vs. OBIO, RCEL, CV, TMCI, and TLSI

How does Hyperfine compare to Orchestra BioMed?

Summary

How does Hyperfine compare to Avita Medical?

Summary

How does Hyperfine compare to CapsoVision?

Summary

How does Hyperfine compare to Treace Medical Concepts?

Summary

How does Hyperfine compare to TriSalus Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPR vs. The Competition

Hyperfine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hyperfine (HYPR) Competitors

HYPR vs. OBIO, RCEL, CV, TMCI, and TLSI

How does Hyperfine compare to Orchestra BioMed?

Does the media prefer OBIO or HYPR?

Which has stronger valuation & earnings, OBIO or HYPR?

Do analysts prefer OBIO or HYPR?

Do institutionals & insiders believe in OBIO or HYPR?

Is OBIO or HYPR more profitable?

Which has more risk and volatility, OBIO or HYPR?

Summary

How does Hyperfine compare to Avita Medical?

Which has higher valuation and earnings, HYPR or RCEL?

Is HYPR or RCEL more profitable?

Does the media favor HYPR or RCEL?

Which has more risk and volatility, HYPR or RCEL?

Do analysts recommend HYPR or RCEL?

Do institutionals and insiders hold more shares of HYPR or RCEL?

Summary

How does Hyperfine compare to CapsoVision?

Which has preferable valuation & earnings, CV or HYPR?

Do analysts rate CV or HYPR?

Does the media refer more to CV or HYPR?

Which has more volatility and risk, CV or HYPR?

Do institutionals and insiders believe in CV or HYPR?

Is CV or HYPR more profitable?

Summary

How does Hyperfine compare to Treace Medical Concepts?

Which has better valuation and earnings, HYPR or TMCI?

Is HYPR or TMCI more profitable?

Do insiders & institutionals believe in HYPR or TMCI?

Do analysts rate HYPR or TMCI?

Does the media prefer HYPR or TMCI?

Which has more risk and volatility, HYPR or TMCI?

Summary

How does Hyperfine compare to TriSalus Life Sciences?

Which has more risk & volatility, TLSI or HYPR?

Is TLSI or HYPR more profitable?

Which has better earnings and valuation, TLSI or HYPR?

Does the media refer more to TLSI or HYPR?

Do analysts recommend TLSI or HYPR?

Do institutionals & insiders have more ownership in TLSI or HYPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPR vs. The Competition

Hyperfine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools